JNM (January 2019): Current Treatment Strategies in Metastasized Differentiated Thyroid Cancer
JNM (January 2019): Current Treatment Strategies in Metastasized Differentiated Thyroid Cancer

JNM (January 2019): Current Treatment Strategies in Metastasized Differentiated Thyroid Cancer

JNM, January 2019, Volume 60, Number 1

Member Fee: Free
Non-Member Fee: $15.00

Release Date: January 1, 2019
Expiration Date: January 31, 2022


Authors

Michael C. Kreissl1, Marcel J.R. Janssen2, and James Nagarajah2,3

1Department of Radiology and Nuclear Medicine, University Hospital Magdeburg, Magdeburg, Germany; 2Department of Radiology
and Nuclear Medicine, Radboud University Medical Center, Nijmegen, The Netherlands; and 3Department of Nuclear Medicine,
University Hospital Essen, University of Duisburg-Essen, Duisburg, Germany

Financial Disclosure     

Name 

Role 

Disclosure 

Michael C. Kreissl

Author

Consultant/Advisor to Sanofi, Eisai, GE, Bayer, AstraZeneca, Ipsen, Novartis; Investigator for AstraZeneca, Eisai, Sanofi, GE, Terumo

Marcel J.R. Janssen

Author

Nothing to disclose

James Nagarajah

Author

Nothing to disclose

The JNM editors, reviewers and SNMMI Staff have indicated that they do not have a financial interest, arrangement or affiliation with any commercial organization that may have a direct or indirect interest in the content of manuscripts submitted to JNM.

Todd E. Peterson, PhD 

Chair, Publications Committee 

Johannes Czernin, MD 

Editor-In-Chief 

Heiko Schoder, MD 

Associate Editor, Continuing Education 

Arnold M. Strashun, MD 

Chair, Continuing Education Committee 

Norbert Avril, MD

JNM Reviewer 

David Groheux, MD

JNM Reviewer 

Susan Alexander 

SNMMI Staff, Publications 

Caroline Krystek 

SNMMI Staff, Education 

No Commercial Support was received for this activity

 

The following members of the Publications Committee have no relevant financial relationships to disclose. 

Danny A. Basso, CNMT, NCT 

Michael M. Graham, PhD, MD 

Heinrich R. Schelbert, MD, PhD 

Henry F. VanBrocklin, PhD 

Paige B. Bennett, MD 

Hossein Jadvar, MD, PhD, MPH, MBA 

Heiko Schoder, MD 

Harvey A. Ziessman, MD 

Johannes Czernin, MD 

Steven M. Larson, MD, FACNM 

Mathew L. Thakur, PhD 

Rebecca Maxey - SNMMI Staff  

Stanley J. Goldsmith, MD 

Rustain L. Morgan, MD 

Kathy S. Thomas, MHA,CNMT,PET 

 

In accordance with ACCME Revised Standards for Commercial Support and SNMMI Conflict-of-Interest Policy, the planners and authors have indicated no other relevant relationships that could be perceived as a real or apparent conflict of interest. Disclosure of a relationship is not intended to suggest or to condone bias but is made to provide participants with information that might be of potential importance to their evaluation of the activity.  

Target Audience

This article contains information of value to nuclear medicine pharmacists and technologists.


Objectives 

At the completion of this activity, the participant should be able to:

1. Judge the prognosis of patients harboring metastasized differentiated thyroid cancer
2. Identify suitable treatment regimens considering the characteristics of the tumor and the patient’s general condition
3. Describe the basics of radioiodine treatment, TKI treatment, and redifferentiation treatment of metastasized DTC


Continuing Education Credit Information

ACPE (Pharmacists)
The Society for Nuclear Medicine and Molecular Imaging, Inc. (SNMMI) is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity has been designated as knowledge-based CPE. Total available credit for pharmacists is 1.0 hours or 0.10 CEUs. To receive CE credit, learners must achieve a score of 80% on the post-course assessment and complete the evaluation. You will have no more than 3 attempts to successfully complete the post-test. ACPE UPN:
0210-0000-19-904-H04-P.

VOICE (Technologists)
The SNMMI, through its Verification of Involvement in Continuing Education (VOICE) program, has approved this journal article for a maximum of 1.0 continuing education hours (CEHs). VOICE-approved credit is recognized by most licensure states and by the NMTCB and ARRT as Category A+ credit. In order to receive CE credit, you must first complete the activity content. When completed, take the post-test assessment.  You must obtain a score of 80% to receive the CE credit.  You will have no more than 3 attempts to successfully complete the post-test. California Scope: 1.0 Therapy (T).


Minimum system requirements

Supported Operating Systems: Windows (8/7/Vista/XP) or Mac OS X

Supported Internet Browsers: Windows OS Users:
- Microsoft Internet Explorer (version 8 or higher)
- Google Chrome (latest version)
- Mozilla Firefox (latest version)

Supported Internet Browsers: Mac OS X Users:
- Apple Safari (version 4 or higher)
- Google Chrome (latest version)
- Mozilla Firefox (latest version)

Internet Browser Settings:
- Pop-Up Blocker should be disabled
- Java Script should be enabled
- Java should be enabled
- Cookies should be enabled

Plug-ins:
- Adobe Flash Player (http://get.adobe.com/flashplayer/)
- Adobe Acrobat Reader (http://get.adobe.com/reader/)

Hardware Requirements:
- Computer:  1 GHz with 500 MB RAM or better
- Internet Connection:  A broadband connection (DSL, Cable, etc.)
- Sound:  Speakers or headset to hear audio
- Display:  A display screen area of 800 x 600 pixels or higher

Policy on Privacy and Confidentiality: http://www.snmmi.org/index.cfm?PageID=926

For questions please contact the Education Department at Education@snmmi.org 703-708-9000.

© 2019 SNMMI. All rights reserved.   


No relevant financial relationships to disclose.

No relevant financial relationships to disclose.


Type:     Internet Activity (Enduring Material)
93 Registered Users